Related Experiment Video
Updated: Feb 28, 2026
A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
Published on: May 14, 2013
Dual Antiplatelet Therapy Beyond One Year in Patients After Stent Placement: A Review
Jacob D Sumner1, Brianna Zinser1, Andrew Smith2
11 Research Medical Center, Kansas City, MO, USA.
Insights
Dual antiplatelet therapy (DAPT) beyond 12 months may benefit patients after acute coronary syndrome (ACS) events, particularly those with prior myocardial infarction (MI), but bleeding risks must be considered.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Trials
Background:
- Dual antiplatelet therapy (DAPT) is standard after coronary stent placement.
- Optimal DAPT duration post-acute coronary syndrome (ACS) remains an area of active research.
Purpose of the Study:
- To review evidence on the safety and efficacy of continuing DAPT beyond 12 months post-stent placement in ACS patients.
- To evaluate recent clinical trials and guideline updates regarding extended DAPT duration.
Main Methods:
- Systematic review of recent clinical trials.
- Analysis of recommendations from the American College of Cardiology (ACC) and American Heart Association (AHA).
Main Results:
- Prolonged DAPT (beyond 12 months) shows benefit in preventing recurrent cardiovascular events, especially after myocardial infarction (MI).
- Extended DAPT is reasonable for ACS patients without high bleeding risk and no prior bleeding events.
- Increased bleeding risk is a significant consideration with prolonged DAPT.
Conclusions:
- Recent trials support extended DAPT beyond 1 year for select ACS patients.
- Balancing the benefits of reduced CV events against increased bleeding risk is crucial.
- ACC/AHA guidelines now reflect updated recommendations on DAPT duration.
Purpose:
To review the evidence on the safety and efficacy of the continued use of dual antiplatelet therapy (DAPT) beyond 12 months after stent placement in patients following an acute coronary syndrome (ACS) event.
Summary:
Recently, the American College of Cardiology (ACC) and the American Heart Association (AHA) released a focused update on the duration of DAPT in patients with coronary artery disease (CAD). The update makes new recommendations about the duration of DAPT in light of recently performed studies investigating this topic. In regard to patients after an ACS event, the update states it is reasonable to continue DAPT beyond 1 year if these patients are not at a high risk of bleeding and had no overt bleeding while on DAPT. Several trials have been released which aim to provide information about the correct duration of DAPT after an ACS event.
Conclusion:
Recent trials have shown a benefit of prolonged (beyond 12 months) DAPT in preventing recurrent cardiovascular (CV) events in patients, mostly in patients who have had a previous myocardial infarction (MI). These benefits must be weighed with the elevated risks of bleeding.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:27Peripheral Artery Disease III: Interprofessional Care
01:27Coronary Artery Disease V: Interprofessional Care
01:26Angina IV: Management
01:26Atherosclerosis III: Management
01:26Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...